Healthcare / Drug Manufacturers - GeneralKSE
$1362.00
-76.00 (-5.29%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-4.9B · quality 42.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$23.4B
P/E
45.4x
↑EV/EBITDA
14.5x
↑ROE
0.4%
↑Gross Margin
30.5%
↓Debt/Equity
0.50
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+19.8%
FCF CAGR
—
FCF margin
-15.0%
FCF / Net income
-9.87x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $32.82B · net income $498.2M · FCF $-4.92B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $32.82B | $32.82B | $20.21B | $17.26B | $19.10B |
| Net Income | $498.2M | $498.2M | $8.50B | $-14.54B | $-49.55B |
| EBITDA | $5.55B | $5.55B | $5.30B | $3.16B | $-42.05B |
| EPS | 30.00 | 30.00 | 570.00 | -1380.00 | -5910.00 |
| Gross Margin | 30.5% | 30.5% | 38.0% | 37.8% | 34.1% |
| Operating Margin | 4.0% | 4.0% | 7.4% | 5.8% | -1.3% |
| Net Margin | 1.5% | 1.5% | 42.0% | -84.3% | -259.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.50 | 0.50 | 0.30 | 0.03 | 0.35 |
| Current Ratio | 0.32 | 0.32 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.92B | $-4.92B | $1.58B | $-17.89B | $-2.70B |
| Returns | |||||
| ROE | 0.4% | 0.4% | 7.3% | -13.7% | -49.9% |
| Valuation | |||||
| P/E | 45.40 | 45.40 | 4.98 | — | — |
| EV/EBITDA | 14.49 | 14.49 | 9.02 | 8.45 | — |
| P/B | 0.19 | 0.19 | 0.36 | 0.41 | 0.46 |
| Growth & Yield | |||||
| Revenue Growth | 62.4% | 62.4% | 17.1% | -9.6% | — |
| EPS Growth | -94.7% | -94.7% | 141.3% | 76.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
59.1%
EPS terminal req.
$120.85
Spread vs growth
-153.9%
5Y implied EPS CAGR
37.3%
EPS terminal req.
$146.23
Spread vs growth
-132.0%
10Y implied EPS CAGR
22.9%
EPS terminal req.
$235.51
Spread vs growth
-117.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-56.8%
Start / end P/E
5.5x → 45.4x
EPS bridge
570.00 → 30.00
Residual
-683.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.